The second use case, led by the European Medicines Agency (EMA), aims at better understanding the risks of thrombosis in COVID-19 patients. This will demonstrate the possibility for the EMA to conduct studies as part of its regulatory mission, based on EHDS platforms. 

This project will mobilise Danish, Finnish, Croatian and French data and the Darwin Eu Ⓡ network.